From the source
OpenAI has acquired Orchestra Bio, a platform that helps biopharma teams coordinate drug development, and is folding its team and technology into Rosalind, OpenAI's AI models and tools for life sciences research.
- The company says the goal is to help scientists make discoveries and manage the work needed to turn them into treatments that reach patients sooner.
- Orchestra Bio is a platform where people and AI agents work together on drug programs, with scientists and program leaders delegating monitoring and tracking of studies and campaigns to agents.
- OpenAI says a problem in one part of a drug program can affect many others, and Orchestra's agents help teams identify which activities and timelines are affected, gather relevant information and compare ways to respond.
- OpenAI cites its partnership with Novo Nordisk, which it says aims to translate scale and scientific expertise into faster R&D and commercial execution, and work with Moderna, where it says AI is helping teams translate insights from complex data into experimental workflows.
- OpenAI says developing a new medicine takes roughly 10 to 15 years on average from target discovery to regulatory approval in the United States, and that teams often rely on disconnected systems to orchestrate programs.
